Loading clinical trials...

Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

Multi-center, Phase Ⅳ, Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® in Subjects With Essential Blepharospasm

NCT01259557•Medy-Tox

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the treatment of Essential blepharospasm.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and women aged above 18
•Subjects who was diagnosed with Essential Blepharospasm
•Subjects who voluntarily Signed written informed consent
•Subjects who can adhere to protocol and study requirements

Exclusion Criteria

•Subjects with known history of allergy considered due to Botulinum toxin type A
•Subjects who have received botulinum toxin A type within 3 months
•Any disease that might affect neuromuscular function (e.g.. Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis ect.)
•Subjects who are participating in other clinical trials
•Pregnant or lactating female Subjects

Locations (3)

Sevrance Hospital

Seoul, South Korea

Seoul St.Mary Hospital

Seoul, South Korea

Chung-Ang Univesity Yongsan Hospital

Seoul, South Korea

Key Dates

Start Date

August 1, 2010

Primary Completion Date

May 1, 2011

Completion Date

August 1, 2011

Last Updated

April 25, 2012

Enrollment

110

ACTUAL participants

Conditions

Essential Blepharospasm

Interventions

Botulinum Toxin Type A

DRUG

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm

NCT01791881

Essential Blepharospasm

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 25, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions